European Psychiatry - Volume 33 - March 2016

505 / 812

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805 S501
2 El-Menia uneversity, faculty of arts, department of psychology,
El-Menia, Egypt
3 Al-Azhar university, faculty of medicine, department of psychiatry,
Cairo, Egypt
4 Mansoura university, faculty of medicine, department of psychiatry,
Mansoura, Egypt
5 Alexandia university, institute of public health, biostatistics
department, Alexandria, Egypt
6 Ain Shams university, faculty of medicine, department of
psychiatry, Cairo, Egypt
7 Zagazig university, faculty of medicine, psychiatry department,
Zagazig, Egypt
∗ Corresponding author.
Objective to examine the longitudinal effect of depression on
glycemic control in a sample of patients with type 2 diabetes.
Methods the patients were recruited fromdiabetes clinic in Saudi
airlines medical center, in Jeddah, the base line study commu-
nity consisted from 172 patients with type 2 diabetes. They were
assessed for depression using BDI II, and diagnostic interview, and
for diabetic control using HbA1c. We created a person-period data
set for each patient to cover 6 months intervals up to 3 years. We
used generalized estimation equation (GEE) for analysis of longi-
tudinal data. HbA1C was the response variable while depression
and time were the main covariates. Variables were included in
GEE models based on clinical importance and preliminary analy-
sis. Other variables included as covariates were gender, education,
duration of diabetes, co-morbidity and LDL. All statistical analysis
used = 0.05 level of significance and were performed using SPSS
software version 21.
Results Unadjusted HbA1c means were significantly higher in
depressed vs. non-depressed subjects at all time points. The
adjusted HbA1c means in final GEE model were significantly
higher in depressed vs. non-depressed subjects. In all adjusted
models depression was a predictor of glycemic control weather
it was BDI score (estimate = .049, P = .002), diagnoses of MDD
(estimate = 2.038, P = .000), or other depressive diagnosis (esti-
mate = 1.245, P = .000).
Conclusion This study on clinical sample of type 2 diabetic
patients demonstrates that there is a significant longitudinal
relationship between depression and glycemic control and that
depression is associated with persistently higher HbA1c over time.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV477
Reliability and validity of Turkish
version of DSM-5 level 2 Depression
Adult Scale
E. AydIn Asik ∗ . C¸ öldür As¸ c¸ ibas¸ i erdem Alc¸ i
T. Sarikavak , F.P. C¸ ökmüs¸ , S. Öztekin , K. Balikc¸ i ,
S. Yüzeren Bas¸ sivri , O. Aydin , F. Akdeniz ,
D. Sücüllüo˘glu Dikici , E. Köro˘glu , Ö. Aydemir
1 Celal Bayar University Faculty of Medicine, Psychiatry, Manisa,
Turkey
2 Bolu KHB Abant ˙Izzet Baysal University Hospital, Psychiatry, Bolu,
Turkey
3 Boylam Psychiatry Institute, Psychiatry, Ankara, Turkey
∗ Corresponding author.
Objective This study aims to demonstrate the reliability and
validity of Turkish version of DSM-5 level 2 depression adult Scale
which was developed to measure the severity of depression.
Material-methods The study group included 51 patients who
met the criteria for major depressive disorder according to DSM-
5. Sixty-five volunteers without any mental or physical disease
were also recruited as a control group. Beck Depression Inventory
(BDI), which is the most widely used self-report scale, was used for
concurrent validity. Internal consistency coefficient and item-total
correlation analysis were performed for reliability. Exploratory fac-
tor analysis was used for validity as BDI was used for concurrent
validity.
Results Mean age was 40.5 ± 11.4 in the patient group and
21.8± 4.9 years in the control group, respectively. A total of 62.1%
of the sample group (n = 72) were female. A total of 59.5% of the
groupwere college graduates, 16.4%were primary school graduates
and 14.7% were high school graduates. Disease duration for major
depressive disorderwas 13.5 ± 10.5 years for the patient group. The
internal consistency of the Level 2 Depression Adult was 0.96. Item-
total correlation coefficients were between 0.71–0.90 (P < 0.0001).
For the exploratory factor analysis of sample adequacy of DSM-5
Level 2 Depression Adult Scale, Kaiser-Meger-Olkin (KMO) coeffi-
cient and Bartlett coefficient was calculated as 0.91 and 1026, 62
(P < 0.0000), respectively. Single-factor solution was obtained with
aneigen value of 6.27, representing 78.3% of the variance. Factor
loadings of the items were between 0.77–0.92. Correlation coef-
ficient of Level 2 Depression Adult Scale with BDI was found as
r= 0.76 (P < 0.0000).
Conclusion The Turkish version of DSM-5 Level 2 Depression
Adult Scale is reliable and valid.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV478
Agomelatine vs fluoxetine: Efficacy
and improvement of cognitive
functions in patients with MDD
E. Aydın ∗, M. Gülec¸ , E. Oral , A.G. Dalo˘glu
1 Atatürk University School of Medicine, Psychiatry, Erzurum, Turkey
2 ˙Izmir Katip C¸ elebi University School of Medicine, Psychiatry, ˙Izmir,
Turkey
3 Mersin State Hospital, Psychiatry, Mersin, Turkey
∗ Corresponding author.
Introduction In major depressive disorder (MDD) neurocogni-
tive functions are impaired. In addition to melatonergic properties
of agomelatine, via 5-HT2C antagonism it increases extracellular
noradrenaline and dopamine in frontal cortex and may improve
the neurocognitive functions of patients with MDD.
Aims and objectives To investigate the extent of neurocognitive
improvement and efficacy of agomelatine andfluoxetine inpatients
with MDD.
Material and method Agomelatine 25mg/day (n: 24) and fluoxe-
tine 20mg/day (n: 24) were administered to drug-naive unipolar,
non-psychotic, non-suicidal MDD patients according to DSM-IV.
Evaluations were performed just before the treatment and at
the sixth week of treatment via administering Hamilton Depres-
sion Rating Scale, Rey Auditory Verbal Learning Test, Controlled
Oral Word Association Test (COWAT), Digit Span Test (DST), Trail
Making Test (TMT-A/B), Stroop Test and Wisconsin Card Sorting
Test.
Results Both agomelatine and fluoxetine was found to be effica-
cious for the treatment of MDD (P < 0.05 for both). Further there
was no difference between the antidepressant efficacy of two
drugs. Both of the drugs improved measured neurocognitive func-
tions (P < 0.05), except scores of DST (P > 0.05) and only fluoxetine
improved significantly scores of COWAT (P < 0.05). Only in terms of
TMT-B therewas significant difference between groups and agome-
latine was superior to fluoxetine (P< 0.05).
Conclusion Agomelatine and fluoxetine were efficacious in treat-
ment of MDD. Furthermore both of the drugs improved cognitive
functions in patients with MDD. Superiority of agomelatine in
improvement of executive functioning (TMT-B) is important and
therefore it could be an appropriate choice for MDD patients who
have pronounced executive disturbances.